Terms: = Ovarian cancer AND SDHB, PGL4, 6390, ENSG00000117118, SDH1, SDHIP, SDH, IP AND Treatment
349 results:
1. Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role.
Padilla-Iserte P; Iváñez M; Muruzabal JC; Navarro R; Díaz-Feijoo B; Iacoponi S; García-Pineda V; Díaz C; Utrilla-Layna J; Gil-Moreno A; Serra A; Gilabert-Estellés J; Martínez Canto C; Tejerizo Á; Lago V; Cárdenas-Rebollo JM; Domingo S;
Eur J Surg Oncol; 2024 Apr; 50(4):108263. PubMed ID: 38492526
[TBL] [Abstract] [Full Text] [Related]
2. Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the treatment of ovarian cancer.
Wang JY; Gross M; Urban RR; Jorge S
Curr Treat Options Oncol; 2024 Mar; 25(3):313-329. PubMed ID: 38270801
[TBL] [Abstract] [Full Text] [Related]
3. Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in ovarian cancer Murine Xenografts.
Demuytere J; Carlier C; Van de Sande L; Hoorens A; De Clercq K; Giordano S; Morosi L; Matteo C; Zucchetti M; Davoli E; Van Dorpe J; Vervaet C; Ceelen W
Int J Nanomedicine; 2024; 19():429-440. PubMed ID: 38260242
[TBL] [Abstract] [Full Text] [Related]
4. OTU deubiquitinase 7B facilitates the hyperthermia-induced inhibition of lung cancer progression through enhancing Smac-mediated mitochondrial dysfunction.
Sun C; Bai J; Sun J; Sun Y; Zhang F; Li H; Liu Y; Meng L; Wang X
Environ Toxicol; 2024 Apr; 39(4):1989-2005. PubMed ID: 38088504
[TBL] [Abstract] [Full Text] [Related]
5. CO
Braet H; Fransen PP; Mariën R; Lollo G; Ceelen W; Vervaet C; Balcaen L; Vanhaecke F; Vanhove C; van der Vegte S; Gasthuys E; Vermeulen A; Dankers PYW; De Smedt SC; Remaut K
ACS Appl Mater Interfaces; 2023 Oct; 15(42):49022-49034. PubMed ID: 37819736
[TBL] [Abstract] [Full Text] [Related]
6. Cytoplasmic SIRT1 promotes paclitaxel resistance in ovarian carcinoma through increased formation and survival of polyploid giant cancer cells.
Xu H; Zeng S; Wang Y; Yang T; Wang M; Li X; He Y; Peng X; Li X; Qiao Q; Zhang J
J Pathol; 2023 Oct; 261(2):210-226. PubMed ID: 37565313
[TBL] [Abstract] [Full Text] [Related]
7. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory ovarian cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial.
Holloway RW; Mendivil AA; Kendrick JE; Abaid LN; Brown JV; LeBlanc J; McKenzie ND; Mori KM; Ahmad S
JAMA Oncol; 2023 Jul; 9(7):903-908. PubMed ID: 37227734
[TBL] [Abstract] [Full Text] [Related]
8. Fibroblast Activation Protein-Targeted Radioligand Therapy for treatment of Solid Tumors.
Lindeman SD; Mukkamala R; Horner A; Tudi P; Booth OC; Huff R; Hinsey J; Hovstadius A; Martone P; Zhang F; Srinivasarao M; Cox A; Low PS
J Nucl Med; 2023 May; 64(5):759-766. PubMed ID: 37116911
[TBL] [Abstract] [Full Text] [Related]
9. Histone methyltransferase SETD1A interacts with notch and promotes notch transactivation to augment ovarian cancer development.
Chai H; Pan C; Zhang M; Huo H; Shan H; Wu J
BMC Cancer; 2023 Jan; 23(1):96. PubMed ID: 36707804
[TBL] [Abstract] [Full Text] [Related]
10. Who really benefits from intraperitoneal chemotherapy for advanced ovarian cancer? A treatment-free survival analysis of the AICE trial.
Xiang L; Shen L; Chen Y; Guo Y; Jiang R; Zhang W; Jia H; Wu Z; Zang R
BJOG; 2022 Nov; 129 Suppl 2():32-39. PubMed ID: 36485070
[TBL] [Abstract] [Full Text] [Related]
11. Identification of two theranostic biomarker panels for epithelial ovarian cancer.
Habel A; Xu W; Hadj Ahmed M; Stayoussef M; Bouaziz H; Ayadi M; Mezlini A; Larbi A; Yaacoubi-Loueslati B
Cytokine; 2023 Jan; 161():156051. PubMed ID: 36401984
[TBL] [Abstract] [Full Text] [Related]
12. Metastatic Colon cancer treatment Using S100A9-Targeted Cowpea Mosaic Virus Nanoparticles.
Chung YH; Volckaert BA; Steinmetz NF
Biomacromolecules; 2022 Dec; 23(12):5127-5136. PubMed ID: 36375170
[TBL] [Abstract] [Full Text] [Related]
13. Development of a nanocapsule-loaded hydrogel for drug delivery for intraperitoneal administration.
Teja Surikutchi B; Obenza-Otero R; Russo E; Zelzer M; Golán Cancela I; Costoya JA; Crecente Campo J; José Alonso M; Marlow M
Int J Pharm; 2022 Jun; 622():121828. PubMed ID: 35595041
[TBL] [Abstract] [Full Text] [Related]
14. NAP1L1 promotes tumor proliferation through HDGF/C-JUN signaling in ovarian cancer.
Xiaohua Zhu ; Xie Y; Huang W; Chen Z; Guo S
BMC Cancer; 2022 Mar; 22(1):339. PubMed ID: 35351053
[TBL] [Abstract] [Full Text] [Related]
15. Genome-wide CRISPR/Cas9 library screen identifies PCMT1 as a critical driver of ovarian cancer metastasis.
Zhang J; Li Y; Liu H; Zhang J; Wang J; Xia J; Zhang Y; Yu X; Ma J; Huang M; Wang J; Wang L; Li Q; Cui R; Yang W; Xu Y; Feng W
J Exp Clin Cancer Res; 2022 Jan; 41(1):24. PubMed ID: 35033172
[TBL] [Abstract] [Full Text] [Related]
16. Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial ovarian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020).
Farrell R; Burling M; Lee YC; Pather S; Robledo K; Mercieca-Bebber R; Stockler M;
J Gynecol Oncol; 2022 Jan; 33(1):e1. PubMed ID: 34783204
[TBL] [Abstract] [Full Text] [Related]
17. The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis.
Kim J; Shim MK; Cho YJ; Jeon S; Moon Y; Choi J; Kim J; Lee J; Lee JW; Kim K
Biomaterials; 2021 Dec; 279():121189. PubMed ID: 34695659
[TBL] [Abstract] [Full Text] [Related]
18. ZNF711 down-regulation promotes CISPLATIN resistance in epithelial ovarian cancer via interacting with JHDM2A and suppressing SLC31A1 expression.
Wu G; Peng H; Tang M; Yang M; Wang J; Hu Y; Li Z; Li J; Li Z; Song L
EBioMedicine; 2021 Sep; 71():103558. PubMed ID: 34521054
[TBL] [Abstract] [Full Text] [Related]
19. PIPAC for the treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial.
Raoof M; Malhotra G; Kohut A; O'Leary M; Frankel P; Tran T; Fakih M; Chao J; Lim D; Woo Y; Paz IB; Lew M; Cristea MC; Rodriguez-Rodriguez L; Fong Y; Blakely A; Whelan R; Reymond MA; Merchea A; Dellinger TH
Ann Surg Oncol; 2022 Jan; 29(1):175-185. PubMed ID: 34387765
[TBL] [Abstract] [Full Text] [Related]
20. Lamin-A interacting protein Hsp90 is required for DNA damage repair and chemoresistance of ovarian cancer cells.
Wang Y; Chen Q; Wu D; Chen Q; Gong G; He L; Wu X
Cell Death Dis; 2021 Aug; 12(8):786. PubMed ID: 34381017
[TBL] [Abstract] [Full Text] [Related]
[Next]
